RxDoctor Payments Data

Matthew Rossi, MD

General Practice · Hopedale, ILNPI 1205874310

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 17 payments — averaging $65.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$589
  • Boston Scientific$165
  • Hologic Sales And Service, LLC$113
  • Globus Medical$80
  • Inari Medical, Inc.$69
  • Vertex$60
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$72565%
  • Education$38235%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 80th percentile of 3,816 general practice providers in Illinois.

See all general practice providers in Illinois

Medicare billing

Part B allowed, 2024
$333,387
Medicare patients
697
Services billed
4,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$160,938
EliquisApixaban166$151,423
OzempicSemaglutide114$124,588
EnbrelEtanercept16$117,759
MounjaroTirzepatide78$90,649
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$30,352
XareltoRivaroxaban16$26,260
JanuviaSitagliptin Phosphate16$19,687
Repatha PushtronexEvolocumab18$14,337
MyrbetriqMirabegron15$9,639
Tresiba Flextouch U-100Insulin Degludec15$7,460
TresibaInsulin Degludec16$6,494
Breo ElliptaFluticasone/Vilanterol15$6,306
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,101
Famotidine381$5,940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$15$26,26016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,816 general practice providers in Illinois.

Other general practice in Hopedale

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →